Companies will begin clinical studies on PacMab’s candidate.

Medarex and PacMab will develop Mab-based therapies for blood cancers, under a collaborative agreement between the two firms. “Initially we will focus on the most prevalent form of multiple myeloma,” says Alan Liddle, CEO of PacMab. “At the same time, we will be developing our pipeline of additional drug therapies using our monoclonal antibody technology aimed at other blood disorders with unmet clinical needs.”

The companies plan to begin clinical trials for PacMab’s existing antibody therapeutic in 2007. Through a collaborative development program, the companies intend to use Medarex’ UltiMAb Human Antibody Development System® to generate fully human antibodies for novel disease targets.

Under the terms of the agreement, Medarex and PacMab will share product development and commercialization responsibilities on any antibody products resulting from this collaboration.

Previous articleWyeth Pharmaceuticals Continues Licensing Spree
Next articleMab for Pancreatic Cancer Receives Orphan Drug Designation